Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema

Takhzyro™ (lanadelumab-flyo) is indicated for the preventive treatment of hereditary angioedema (HAE) in patients aged 12 years and older. Image courtesy of Meg Lauber.

  • Takhzyro
  • Takhzyro
  • Takhzyro

Go Top